Therapeutic advances of targeting receptor tyrosine kinases in cancer

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder

Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder.